BD Delivers Kidney Stone Care for Urology Teams with the Elyra™ Thulium Fiber Laser System
Rhea-AI Summary
BD (NYSE:BDX) introduced the Elyra™ Thulium Fiber Laser (TFL) System, an advanced platform for kidney stone and soft tissue procedures. The system is designed to enhance efficiency, versatility, and procedural workflow for urology teams.
The air‑cooled Elyra™ and Elyra™ Plus offer efficient stone dusting, reduced stone migration, intuitive interface, quick startup, customizable presets, and an optional wireless footswitch (Plus only). Elyra™ integrates into BD’s end‑to‑end urologic stone management portfolio and is now available in the United States.
Positive
- Launch of Elyra™ and Elyra™ Plus TFL Systems expands BD’s urologic stone portfolio
- System designed for efficient stone dusting and reduced stone migration in procedures
- Air‑cooled design provides quieter operation and smaller footprint than traditional lasers
- Intuitive interface, quick startup, and presets aim to streamline clinical workflows
- Optional wireless footswitch available on Elyra™ Plus enhances procedural flexibility
- First Elyra™ Plus clinical cases completed with positive user feedback on usability and safety features
Negative
- None.
News Market Reaction – BDX
On the day this news was published, BDX declined 0.48%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 18 | Leadership appointment | Positive | -0.8% | Named new EVP and president for BD Interventional to support growth. |
| May 07 | CFO appointment | Positive | +5.9% | Confirmed long-time BD executive as CFO, emphasizing continuity and discipline. |
| May 07 | Earnings update | Positive | +5.9% | Reported revenue growth, ASR, debt reduction and raised adjusted EPS guidance. |
| May 05 | AI partnership | Positive | -1.5% | Announced AI-enabled medication management partnership with Wellstar Health System. |
| Apr 30 | Workplace recognition | Positive | +2.6% | Received multiple awards for employee health and well-being programs. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent company-specific news, especially leadership and financial updates, has more often aligned positively with share price than not, but there are notable divergences on strategic and partnership news.
Over the last few months, BD has focused on leadership transitions, portfolio optimization and financial discipline. Q2 FY2026 results showed revenue of $4.714 billion and higher adjusted EPS guidance, which coincided with a strong positive price reaction. Executive appointments in finance and interventional units, AI-powered medication management initiatives, and recognition for employee well-being round out a mix of operational and strategic updates. Today’s kidney stone care system introduction adds a product-focused development to this trajectory.
Key Terms
thulium fiber laser medical
stone lithotripsy medical
urologic stone management medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
New laser system is designed to help urology teams enhance efficiency, versatility, and procedural workflow across stone management and soft tissue procedures.
FRANKLIN LAKES, N.J., May 21, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the introduction of the Elyra™ Thulium Fiber Laser (TFL) System, an advanced laser platform developed to complete BD's kidney stone care portfolio for urology teams. Designed to enhance efficiency, versatility, and procedural workflow across urologic stone management and soft tissue procedures, the innovative new system supports consistent performance in demanding clinical environments.
The Elyra™ TFL System leverages Thulium Fiber Laser technology to support efficient stone dusting and reduced stone migration, while its air-cooled design offers quieter operation and a smaller footprint compared to traditional laser systems. The platform is available in two configurations—Elyra™ and Elyra™ Plus—offering flexibility to select the system that best aligns with varying operational needs. Designed with procedural efficiency in mind, the Elyra™ TFL System features an intuitive user interface, quick startup, customizable presets, and an optional wireless footswitch1 to help streamline workflows in stone lithotripsy and soft tissue procedures.
"Elyra™ demonstrates how BD innovates with speed and purpose, introducing technology that helps clinicians deliver high‑quality care more efficiently," said Mike Cusack, worldwide president of Urology and Critical Care at BD. "By pairing advanced TFL technology with a clinician‑focused design, Elyra™ streamlines kidney stone care and supports greater adaptability across diverse procedural needs."
Developed by BD, the platform enables agility in advancing future generations of the technology, allowing the company to respond quickly to evolving clinician and patient needs. BD recently completed its first clinical cases using the Elyra™ Plus TFL System at a leading medical center where the system received positive feedback from urologists and laser technicians who engaged with the laser. Users noted the intuitive interface and integrated safety features, which supported ease of use and confidence during procedures.
With Elyra™, BD continues to expand its urologic stone management portfolio, integrating with solutions spanning access, dilation, visualization, fragmentation, removal and drainage, supporting providers with an end-to-end approach across every step. Elyra ™ helps practices optimize performance today while preparing for the future of urologic care.
The Elyra™ and Elyra™ Plus TFL Systems are now available in
1 | Wireless footswitch only available with Elyra™ Plus |
About BD
BD is one of the world's largest pure-play medical technology companies with a Purpose of advancing the world of health™ by driving innovation across medical essentials, connected care, biopharma systems and interventional. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions that optimize clinical operations and improve care for patients. Operating across the globe, with more than 60,000 employees, BD delivers billions of products annually that have a positive impact on global healthcare. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase clinical efficiency, improve safety and expand access to healthcare. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X @BDandCo or Instagram @becton_dickinson.
Contacts: | |
Media | Investors |
Matt Marcus | Shawn Bevec SVP, Investor Relations |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-delivers-kidney-stone-care-for-urology-teams-with-the-elyra-thulium-fiber-laser-system-302778493.html
SOURCE BD (Becton, Dickinson and Company)